Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 287

1.

Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial.

Yamada Y, Boku N, Mizusawa J, Iwasa S, Kadowaki S, Nakayama N, Azuma M, Sakamoto T, Shitara K, Tamura T, Chin K, Hata H, Nakamori M, Hara H, Yasui H, Katayama H, Fukuda H, Yoshikawa T, Sasako M, Terashima M.

Lancet Gastroenterol Hepatol. 2019 Jul;4(7):501-510. doi: 10.1016/S2468-1253(19)30083-4. Epub 2019 May 14.

PMID:
31101534
2.

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.

Shitara K, Iwata H, Takahashi S, Tamura K, Park H, Modi S, Tsurutani J, Kadowaki S, Yamaguchi K, Iwasa S, Saito K, Fujisaki Y, Sugihara M, Shahidi J, Doi T.

Lancet Oncol. 2019 Jun;20(6):827-836. doi: 10.1016/S1470-2045(19)30088-9. Epub 2019 Apr 29. Erratum in: Lancet Oncol. 2019 May 10;:.

PMID:
31047804
3.

A Phase I Study of Napabucasin Plus Paclitaxel for Japanese Patients With Advanced/Recurrent Gastric Cancer.

Shitara K, Yodo Y, Iino S.

In Vivo. 2019 May-Jun;33(3):933-937. doi: 10.21873/invivo.11561.

4.

PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.

Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, Sato E, Fukuoka S, Tada Y, Tanaka A, Morikawa H, Kawazoe A, Kinoshita T, Shitara K, Sakaguchi S, Nishikawa H.

Proc Natl Acad Sci U S A. 2019 May 14;116(20):9999-10008. doi: 10.1073/pnas.1822001116. Epub 2019 Apr 26.

5.

Dawn of precision medicine on gastric cancer.

Ishii T, Kawazoe A, Shitara K.

Int J Clin Oncol. 2019 Jul;24(7):779-788. doi: 10.1007/s10147-019-01441-x. Epub 2019 Apr 11. Review.

PMID:
30976939
6.

The KEYNOTE-061 trial - Authors' reply.

Shitara K, Chen X.

Lancet. 2019 Mar 16;393(10176):1099. doi: 10.1016/S0140-6736(18)33076-9. Epub 2019 Mar 14. No abstract available.

PMID:
30894266
7.

KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer.

Bang YJ, Van Cutsem E, Fuchs CS, Ohtsu A, Tabernero J, Ilson DH, Hyung WJ, Strong VE, Goetze TO, Yoshikawa T, Tang LH, Hwang PMT, Webb N, Adelberg D, Shitara K.

Future Oncol. 2019 Mar;15(9):943-952. doi: 10.2217/fon-2018-0581. Epub 2019 Feb 19.

8.

Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors.

Doi T, Yang JC, Shitara K, Naito Y, Cheng AL, Sarashina A, Pronk LC, Takeuchi Y, Lin CC.

Target Oncol. 2019 Feb;14(1):57-65. doi: 10.1007/s11523-019-00620-0.

9.

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.

Fuchs CS, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran SE, Van Cutsem E, Ilson DH, Alsina M, Chau I, Lacy J, Ducreux M, Mendez GA, Alavez AM, Takahari D, Mansoor W, Enzinger PC, Gorbounova V, Wainberg ZA, Hegewisch-Becker S, Ferry D, Lin J, Carlesi R, Das M, Shah MA; RAINFALL Study Group.

Lancet Oncol. 2019 Mar;20(3):420-435. doi: 10.1016/S1470-2045(18)30791-5. Epub 2019 Feb 1. Erratum in: Lancet Oncol. 2019 May;20(5):e242.

PMID:
30718072
10.

Regulatory T cells in cancer immunosuppression - implications for anticancer therapy.

Togashi Y, Shitara K, Nishikawa H.

Nat Rev Clin Oncol. 2019 Jun;16(6):356-371. doi: 10.1038/s41571-019-0175-7. Review.

PMID:
30705439
11.

Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer.

Mishima S, Kawazoe A, Nakamura Y, Sasaki A, Kotani D, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Kuwata T, Tsuji A, Shitara K.

J Immunother Cancer. 2019 Jan 31;7(1):24. doi: 10.1186/s40425-019-0514-3.

12.

[Two Cases of Surgical Treatment for Disseminated Gastric Carcinoma].

Aoki M, Fukunari H, Kawai Y, Watanabe A, Umebayashi Y, Saito T, Shitara K, Hayashi T, Alexey A, Ajioka Y.

Gan To Kagaku Ryoho. 2018 Dec;45(13):2378-2380. Japanese.

PMID:
30692470
13.

[A Case of Recurrent Gastric Cancer with No. 13 Lymph Node Metastasis Treated with SurgicalResection].

Saito T, Hayashi T, Aoki M, Watanabe A, Umebayashi Y, Shitara K, Fukunari H.

Gan To Kagaku Ryoho. 2018 Dec;45(13):2363-2365. Japanese.

PMID:
30692465
14.

[A Case of Choriocarcinoma of the Small Intestine with Multiple Lung and Liver Metastases].

Watanabe A, Fukunari H, Aoki M, Saito S, Shitara K, Hayashi T, Tani Y, Ajioka Y.

Gan To Kagaku Ryoho. 2018 Dec;45(13):2102-2104. Japanese.

PMID:
30692298
15.

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors.

Shimomura A, Yamamoto N, Kondo S, Fujiwara Y, Suzuki S, Yanagitani N, Horiike A, Kitazono S, Ohyanagi F, Doi T, Kuboki Y, Kawazoe A, Shitara K, Ohno I, Banerji U, Sundar R, Ohkubo S, Calleja EM, Nishio M.

Mol Cancer Ther. 2019 Mar;18(3):531-540. doi: 10.1158/1535-7163.MCT-18-0831. Epub 2019 Jan 24.

PMID:
30679388
16.

Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.

Sasaki A, Nakamura Y, Mishima S, Kawazoe A, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Kuwata T, Akimoto T, Shitara K.

Gastric Cancer. 2019 Jul;22(4):793-802. doi: 10.1007/s10120-018-00922-8. Epub 2019 Jan 9.

PMID:
30627987
17.

Reply to: "Multimodal Treatment of Locally Advanced Gastric Cancer: Will the West Meet the East?", by Marino, Elisabetta et al.

Nakamura Y, Yamanaka T, Shitara K.

Ann Surg Oncol. 2019 Mar;26(3):919-920. doi: 10.1245/s10434-018-07142-5. Epub 2019 Jan 4. No abstract available.

PMID:
30610558
18.

REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients.

Shitara K, Yamanaka T, Denda T, Tsuji Y, Shinozaki K, Komatsu Y, Kobayashi Y, Furuse J, Okuda H, Asayama M, Akiyoshi K, Kagawa Y, Kato T, Oki E, Ando T, Hagiwara Y, Ohashi Y, Yoshino T.

Ann Oncol. 2019 Feb 1;30(2):259-265. doi: 10.1093/annonc/mdy526.

PMID:
30508156
19.

First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors.

Doi T, Yoh K, Shitara K, Takahashi H, Ueno M, Kobayashi S, Morimoto M, Okusaka T, Ueno H, Morizane C, Okano N, Nagashima F, Furuse J.

Invest New Drugs. 2019 Jun;37(3):507-518. doi: 10.1007/s10637-018-0697-3. Epub 2018 Dec 4.

20.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS.

Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Kato K, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Nakajima TE, Shitara K, Kawakami H, Tsushima T, Yoshino T, Lordick F, Martinelli E, Smyth EC, Arnold D, Minami H, Tabernero J, Douillard JY.

Ann Oncol. 2019 Jan 1;30(1):19-33. doi: 10.1093/annonc/mdy502.

PMID:
30475956
21.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS.

Muro K, Lordick F, Tsushima T, Pentheroudakis G, Baba E, Lu Z, Cho BC, Nor IM, Ng M, Chen LT, Kato K, Li J, Ryu MH, Zamaniah WIW, Yong WP, Yeh KH, Nakajima TE, Shitara K, Kawakami H, Narita Y, Yoshino T, Van Cutsem E, Martinelli E, Smyth EC, Arnold D, Minami H, Tabernero J, Douillard JY.

Ann Oncol. 2019 Jan 1;30(1):34-43. doi: 10.1093/annonc/mdy498.

PMID:
30475943
22.

Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy.

Nakamura Y, Yamanaka T, Chin K, Cho H, Katai H, Terashima M, Misawa K, Hirao M, Yoshida K, Oki E, Sasako M, Emi Y, Bando H, Kawashima Y, Fukunaga T, Gotoh M, Ishibashi T, Shitara K.

Ann Surg Oncol. 2019 Feb;26(2):465-472. doi: 10.1245/s10434-018-7063-8. Epub 2018 Nov 19.

PMID:
30456678
23.

Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma.

Mishima S, Kawazoe A, Matsumoto H, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Nonte EM, Chintharlapalli S, Nasir A, Kuwata T, Shitara K.

ESMO Open. 2018 Nov 1;3(7):e000443. doi: 10.1136/esmoopen-2018-000443. eCollection 2018.

24.

Four cases of paradoxical cephalocervical pyogenic granuloma during treatment with paclitaxel and ramucirumab.

Watanabe R, Nakano E, Kawazoe A, Kuboki Y, Bando H, Shitara K, Takahashi A, Tsutsumida A, Nishizawa A, Yamazaki N.

J Dermatol. 2019 May;46(5):e178-e180. doi: 10.1111/1346-8138.14693. Epub 2018 Oct 31. No abstract available.

PMID:
30379358
25.

Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.

Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, Alsina M, Ghidini M, Faustino C, Gorbunova V, Zhavrid E, Nishikawa K, Hosokawa A, Yalçın Ş, Fujitani K, Beretta GD, Van Cutsem E, Winkler RE, Makris L, Ilson DH, Tabernero J.

Lancet Oncol. 2018 Nov;19(11):1437-1448. doi: 10.1016/S1470-2045(18)30739-3. Epub 2018 Oct 21. Erratum in: Lancet Oncol. 2018 Dec;19(12):e668.

PMID:
30355453
26.

Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment.

Tada Y, Togashi Y, Kotani D, Kuwata T, Sato E, Kawazoe A, Doi T, Wada H, Nishikawa H, Shitara K.

J Immunother Cancer. 2018 Oct 11;6(1):106. doi: 10.1186/s40425-018-0403-1.

27.

Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0).

Sunami K, Takahashi H, Tsuchihara K, Takeda M, Suzuki T, Naito Y, Sakai K, Dosaka-Akita H, Ishioka C, Kodera Y, Muto M, Wakai T, Yamazaki K, Yasui W, Bando H, Fujimoto Y, Fukuoka S, Harano K, Kawazoe A, Kimura G, Koganemaru S, Kogawa T, Kotani D, Kuboki Y, Matsumoto H, Matsumoto S, Mishima S, Nakamura Y, Sawada K, Shingaki S, Shitara K, Umemoto K, Umemura S, Yasuda K, Yoshino T, Yamamoto N, Nishio K; Japanese Society of Medical Oncology; Japan Society of Clinical Oncology; Japanese Cancer Association.

Cancer Sci. 2018 Sep;109(9):2980-2985. doi: 10.1111/cas.13730.

28.

Chemical Pressure-Induced Anion Order-Disorder Transition in LnHO Enabled by Hydride Size Flexibility.

Yamashita H, Broux T, Kobayashi Y, Takeiri F, Ubukata H, Zhu T, Hayward MA, Fujii K, Yashima M, Shitara K, Kuwabara A, Murakami T, Kageyama H.

J Am Chem Soc. 2018 Sep 12;140(36):11170-11173. doi: 10.1021/jacs.8b06187. Epub 2018 Aug 28.

PMID:
30126273
29.

Dose-finding study of the checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors.

Iwasa S, Yamamoto N, Shitara K, Tamura K, Matsubara N, Tajimi M, Lin AB, Asou H, Cai Z, Inoue K, Shibasaki Y, Saito K, Takai H, Doi T.

Cancer Sci. 2018 Oct;109(10):3216-3223. doi: 10.1111/cas.13750.

30.

Human epidermal growth factor receptor 2-, epidermal growth factor receptor-, and mesenchymal epithelial transition factor-positive sites of gastric cancer using surgical samples.

Oono Y, Kuwata T, Takashima K, Shinmura K, Hori K, Yoda Y, Ikematsu H, Shitara K, Kinoshita T, Yano T.

Gastric Cancer. 2019 Mar;22(2):335-343. doi: 10.1007/s10120-018-0853-7. Epub 2018 Jun 27.

PMID:
29951752
31.

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.

Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung HC, Muro K, Goekkurt E, Mansoor W, McDermott RS, Shacham-Shmueli E, Chen X, Mayo C, Kang SP, Ohtsu A, Fuchs CS; KEYNOTE-061 investigators.

Lancet. 2018 Jul 14;392(10142):123-133. doi: 10.1016/S0140-6736(18)31257-1. Epub 2018 Jun 4.

PMID:
29880231
32.

Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer.

Kawazoe A, Shitara K, Kuboki Y, Bando H, Kojima T, Yoshino T, Ohtsu A, Ochiai A, Togashi Y, Nishikawa H, Doi T, Kuwata T.

Gastric Cancer. 2019 Jan;22(1):69-76. doi: 10.1007/s10120-018-0843-9. Epub 2018 Jun 1.

PMID:
29859006
33.

Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial.

Takashima A, Shitara K, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Kimura Y, Amagai K, Fujii H, Muro K, Esaki T, Choda Y, Takano T, Chin K, Sato A, Goto M, Fukushima N, Hara T, Machida N, Ohta M, Boku N, Shimura M, Morita S, Koizumi W.

Gastric Cancer. 2019 Jan;22(1):155-163. doi: 10.1007/s10120-018-0838-6. Epub 2018 May 31.

34.

Tuberculous Meningitis during Chemotherapy for Advanced Gastric Cancer.

Matsumoto H, Sasaki A, Nakamura Y, Kawazoe A, Kuboki Y, Okinaka K, Shitara K.

Case Rep Oncol. 2018 Apr 5;11(1):228-233. doi: 10.1159/000488313. eCollection 2018 Jan-Apr.

35.

Feasibility study of cancer genome alterations identified by next generation sequencing: ABC study.

Naito Y, Takahashi H, Shitara K, Okamoto W, Bando H, Kuwata T, Kuboki Y, Matsumoto S, Miki I, Yamanaka T, Watanabe A, Kojima M.

Jpn J Clin Oncol. 2018 Jun 1;48(6):559-564. doi: 10.1093/jjco/hyy052.

36.

Regulatory T cells: a potential target in cancer immunotherapy.

Shitara K, Nishikawa H.

Ann N Y Acad Sci. 2018 Apr;1417(1):104-115. doi: 10.1111/nyas.13625. Epub 2018 Mar 22. Review.

PMID:
29566262
37.

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.

Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH.

JAMA Oncol. 2018 May 10;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013. Epub 2018 May 10.

38.

Clinicopathological features and endoscopic findings of HER2-positive gastric cancer.

Oono Y, Kuwata T, Takashima K, Yoda Y, Ikematsu H, Shitara K, Kinoshita T, Yano T.

Surg Endosc. 2018 Sep;32(9):3964-3971. doi: 10.1007/s00464-018-6138-8. Epub 2018 Mar 2.

PMID:
29500656
39.

[Hemosuccus Pancreaticus Due to Pancreatic Head Invasive Pancreatic Duct Carcinoma].

Kawai Y, Hayashi T, Aoki M, Umebayashi Y, Saito T, Watanabe A, Shitara K, Fukunari H, Ajioka Y.

Gan To Kagaku Ryoho. 2018 Feb;45(2):362-364. Japanese.

PMID:
29483448
40.

[A Resected Case of Long-Term Survival of Pancreatic Cancer with Simultaneous Multiple Lung Metastasis with Systemic Chemotherapy].

Umebayashi Y, Fukunari H, Kawai Y, Aoki M, Watanabe A, Saito T, Shitara K, Hayashi T, Nishikura K, Watanabe G, Ajioka Y.

Gan To Kagaku Ryoho. 2018 Feb;45(2):291-293. Japanese.

PMID:
29483424
41.

[Hepatic Lateral Segmentectomy for Management of Liver and Adrenal Abscess Following a Laparoscopy-Assisted Left Hemicolectomy - A Case Report].

Aoki M, Fukunari H, Kawai Y, Watanabe A, Umebayashi Y, Saito T, Shitara K, Hayashi T.

Gan To Kagaku Ryoho. 2017 Nov;44(12):1135-1137. Japanese.

PMID:
29394558
42.

[A Patient with Basaloid Carcinoma of the Esophagus Removed Surgically after Pre-Operative Chemotherapy Who Developed TTP during Post-Operative Chemotherapy].

Watanabe A, Fukunari H, Kawai Y, Aoki M, Saito S, Umebayashi Y, Shitara K, Hayashi T, Watanabe G, Ajioka H.

Gan To Kagaku Ryoho. 2017 Nov;44(12):1110-1113. Japanese.

PMID:
29394550
43.

A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites.

Matsumoto H, Kawazoe A, Shimada K, Fukuoka S, Kuboki Y, Bando H, Kojima T, Ohtsu A, Yoshino T, Doi T, Shitara K.

BMC Cancer. 2018 Jan 31;18(1):120. doi: 10.1186/s12885-018-4057-7.

44.

A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.

Bando H, Shimodaira H, Fujitani K, Takashima A, Yamaguchi K, Nakayama N, Takahashi T, Oki E, Azuma M, Nishina T, Hironaka S, Komatsu Y, Shitara K.

Eur J Cancer. 2018 Mar;91:86-91. doi: 10.1016/j.ejca.2017.11.032. Epub 2018 Jan 30.

45.

Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer.

Shitara K, Kim TM, Yokota T, Goto M, Satoh T, Ahn JH, Kim HS, Assadourian S, Gomez C, Harnois M, Hamauchi S, Kudo T, Doi T, Bang YJ.

Oncotarget. 2017 Jun 16;8(45):79546-79555. doi: 10.18632/oncotarget.18554. eCollection 2017 Oct 3.

46.

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.

Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, Kitano A, Jikoh T, Lee C, Fujisaki Y, Ogitani Y, Yver A, Tamura K.

Lancet Oncol. 2017 Nov;18(11):1512-1522. doi: 10.1016/S1470-2045(17)30604-6. Epub 2017 Oct 13.

PMID:
29037983
47.

Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.

Shinozaki E, Yoshino T, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shitara K, Bando H, Mimaki S, Nakai C, Matsushima K, Suzuki Y, Akagi K, Yamanaka T, Nomura S, Fujii S, Esumi H, Sugiyama M, Nishida N, Mizokami M, Koh Y, Abe Y, Ohtsu A, Tsuchihara K.

Br J Cancer. 2017 Nov 7;117(10):1450-1458. doi: 10.1038/bjc.2017.308. Epub 2017 Oct 3.

48.

[Cytotoxic Agents and Immune Checkpoint Inhibitors].

Kawazoe A, Shitara K.

Gan To Kagaku Ryoho. 2017 Sep;44(9):717-721. Japanese.

PMID:
28912395
49.

TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study.

Kuboki Y, Nishina T, Shinozaki E, Yamazaki K, Shitara K, Okamoto W, Kajiwara T, Matsumoto T, Tsushima T, Mochizuki N, Nomura S, Doi T, Sato A, Ohtsu A, Yoshino T.

Lancet Oncol. 2017 Sep;18(9):1172-1181. doi: 10.1016/S1470-2045(17)30425-4. Epub 2017 Jul 28.

PMID:
28760399
50.

Safety, pharmacokinetic, and clinical activity profiles of ramucirumab in combination with three platinum/fluoropyrimidine doublets in Japanese patients with chemotherapy-naïve metastatic gastric/gastroesophageal junction cancer.

Shitara K, Kadowaki S, Nishina T, Sakai D, Yoshikawa R, Piao Y, Ozeki A, Inoue K, Gritli I, Muro K.

Gastric Cancer. 2018 Jan;21(1):106-113. doi: 10.1007/s10120-017-0745-2. Epub 2017 Jun 30.

PMID:
28667466

Supplemental Content

Loading ...
Support Center